Key result
Higher serum cholinesterase linked to ~22% lower AF prevalence in hypertensive patients.
Why the study?
Serum cholinesterase levels are elevated in individuals with fatty liver and NAFLD correlates with AF, but the relationship between the serum cholinesterase index and AF remains unclear.
Is serum cholinesterase level associated with the prevalence of atrial fibrillation in patients with hypertension?
Cross-Sectional (n=784)
No
Is serum cholinesterase level associated with the prevalence of atrial fibrillation in patients with hypertension?
Effect estimate: OR 0.778 (95% CI 0.682-0.889)
p-value: p=<0.001
Lower serum cholinesterase levels are independently associated with a higher prevalence of atrial fibrillation in hypertensive patients, suggesting its potential utility as a predictive biomarker.
Hypothesis-generating for cholinesterase as AF biomarker in hypertension; prospective studies needed before clinical use.
BACKGROUND: Atrial fibrillation (AF) is a very common arrhythmia with significant incidence rate and mortality. Several studies have shown a notable correlation between non-alcoholic fatty liver disease (NAFLD) and AF. It has been observed that serum cholinesterase (SChE) levels are elevated in individuals with fatty liver. However, the relationship between the SChE index and AF is still unclear. Therefore, the purpose of this study is to explore the association between the SChE index and the prevalence of AF in patients with hypertension. METHOD: We collected cross-sectional data from January 2018 to April 2021 based on a retrospective study of cardiovascular disease. A total of 748 patients with hypertension were included, of whom 165 had AF. We used logistic regression models to test the relationship between SChE and the prevalence of AF in hypertensive patients. RESULT: In hypertensive patients, the SChE index was significantly associated with AF (OR = 0.723, P < 0.001). After adjusting for potential confounding factors, this correlation was still significant (OR = 0.778, P < 0.001). The stability of the model was verified by adjusting the variable type of SChE. The data were further stratified according to whether the patient had fatty liver. In the stratified data, the correlation between SChE and atrial fibrillation was still significant (P < 0.05). CONCLUSION: Our study showed that SChE was significantly negatively correlated with the occurrence of AF in patients with hypertension. And this correlation was not affected by whether the patient had fatty liver.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2023) conducted a cross-sectional in Hypertension (n=784). Serum cholinesterase (SChE) was evaluated on Prevalence of atrial fibrillation (OR 0.778, 95% CI 0.682-0.889, p=<0.001). Higher serum cholinesterase levels were significantly associated with a lower prevalence of atrial fibrillation in hypertensive patients (OR 0.778).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: